Acute myeloid leukemias secondary (sAML) to myeloproliferative neoplasms (MPN) have variable clinical courses and outcomes, but remain almost always fatal. Large cohorts of sAML to MPN are difficult to obtain and there is very little scientific literature or prospective trials for determining robust prognostic markers and efficient treatments. We analyzed event-free survival (EFS) and overall survival (OS) of 73 patients with MPN who progressed to sAML, based on their epidemiological characteristics, the preexisting MPN, the different treatments received, the different prognostic groups and the responses achieved according to the ELN, and their mutational status determined by next-generation DNA sequencing (NGS). For 24 patients, we were able to do a comparative NGS analysis at both MPN and sAML phase. After acute transformation EFS and OS were respectively of 2.9 months (range: 0-48.1) and 4.7 months (range: 0.1-58.8). No difference in EFS or OS regarding the previous MPN, the ELN2017 prognostic classification, the first-line therapy or the response was found. After univariate analysis, three genes, TP53, SRSF2 and TET2, impacted pejoratively sAML prognosis at sAML time. In multivariate analysis, TP53 (P 5 .0001), TET2 (P 5 .011) and SRSF2 (P 5 .018) remained independent prognostic factors. Time to sAML transformation was shorter in SRSF2-mutated patients (51.2 months, range: 14.7-98) than in SRSF2-unmutated patients (133.8 months, range: 12.6-411.2) (P < .001). Conventional clinical factors (age, karyotype, ELN2017 prognostic classification, treatments received, treatments response, Allo-SCT. . .) failed to predict the patients' outcome. Only the mutational status appeared relevant to predict patients' prognosis at sAML phase.
| B AC KGR OUND
Leukemic transformation of BCR-ABL1-negative myeloproliferative neoplasms (MPN) occurs in 8% to 23% of primary myelofibrosis (PMF) patients in the first 10 years after diagnosis and in 4% to 8% of polycythemia vera (PV) and essential thrombocytis (ET) patients within 18 years after diagnosis and is almost always fatal. 1 Acute myeloid leukemias secondary (sAML) to MPN have variable clinical courses and outcomes. [2] [3] [4] Large cohorts of sAML to MPN are difficult to obtain and there is little scientific literature or prospective trials for determining the best treatment strategies.
There is no specific treatment for post MPN sAML. Classical AMLtype induction regimen like 3 1 7 are used in eligible patients but the response rate is low, toxicity and mortality high with poor long term results. 5 Encouraging results have been obtained with hypomethylating agents but data are still limited and confirmation is warranted. 6 generally excluded from large multicenter AML trials and few dedicated studies have been conducted so far.
Most of BCR-ABL1-negative MPNs have recurrent somatic driver mutations in either Janus kinase 2 (JAK2), calreticulin (CALR) exon 9 or myeloproliferative leukemia virus oncogene (MPL). Survival and blast transformation rates differ between PV, ET, and PMF according to their specific cytogenetic abnormalities or mutational status at MPN phase. 1, 7, 8 However, little is known of the impact of mutational status at leukemic transformation time and whether it may add information to conventional prognostic stratification systems.
In a previous study, we described genetic events occurring during acute transformation of MPN. 9 Here, we have enriched our cohort in post MPN sAML cases and we have studied and analyzed EFS and OS of 73 patients with MPN who progressed to sAML. The objectives of this retrospective study were to compare treatment options, assess in this cohort the value of currently used response criteria, the prognostic relevance of the recently proposed ELN2017 genomic risk stratification and of gene mutations. 5 
| M E TH ODS

| Treatments received and therapeutic response
The treatments received by the patients were classified in three groups. The first group referred to as intensive chemotherapy (IC) In addition, the JAK2V617F mutation was also determined by realtime quantitative PCR; MPLW515 was detected by Sanger sequencing and CALR exon 9 mutations were determined as previously described by fragment analysis techniques followed by Sanger sequencing. 10 
| Statistical analysis
Correlations between mutated genes and factors considered as contin- 
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| Treatment and response
As shown in Table S3 ). However, as shown in Figure 1A and Supporting Information Figure S1A , no difference in EFS (P 5 .4443) or OS (0.9842) was found between IC and AZA treatment groups. IC and AZA produced similar overall response rate (ORR) (respectively 58.8% vs.
54.6%) and day-30 mortality rate were respectively 8.8% vs.0%.
Treatment response was evaluated in the 45 patients treated actively (IC and AZA groups) according to the ELN2017 response criteria: 12 (26.7%) were in complete remission (CR), 8 (17.8%) were in complete remission with incomplete hematologic recovery (CRi), 10 (22.2%) presented a primary refractory disease (PRD), 1 patient was in partial remission (PR) (2.2%), 5 patients were in stable disease (SD) (11.1%), 3 patients (6.7%) were in progression disease (PD), 3 deceased in aplasia (6.7%) and 3 patients were not evaluable (6.7%). OS were evaluated according to the ELN2017 response criteria. In univariate analysis, patients in CR/CRi after the first-line therapy had a better OS than patients in PRD/PR/SD/PD (P 5 .0061). However, after regression logistic, this result did not remain significant (Supporting Information Table S3 ). As shown in Figure 1B , after landmark analysis, OS was respectively of 9.9 months (range: 2. NS) ( Figure 1C and Supporting Information Table S3 ). Figure S2 ).
| Prognostic factors and patients outcome
According to ELN 2017, among the 73 sAML patients, 3 (4.1%), 10 (13.7%) and 46 (63%) respectively belonged to the favorable, intermediate and adverse risk category. Given the small number of patients in the favorable (Fav) (n 5 3) and intermediate (Int) (n 5 10) categories, these two groups were merged in the survival analysis. As shown in Figure 1D and Supporting Information Figure S1B, 
| NGS analysis and impact of the mutational status on patient's outcome
Among the 73 sAMLs, 56 were studied by NGS. Forty three genes were mutated in the total cohort with a mean of 3.5 genes mutated Table S3 ).
As shown in Figure 3A , patients with TP53 mutation had a shorter Figure S3 ).
Patients with a TET2 mutation had a shorter OS (2.3 months, range: 0.2-25.4) than patients with TET2 WT (5.8 months, range: 0.2-58.8) (P 5 .029) ( Figure 3B ). In the same way, patients with SRSF2 mutation had a shorter OS (2.7 month, range: 0.3-25.4) than patients with SRSF2 WT (5.9 months, range: 0.2-58.8) (P 5 .034) ( Figure 3C ).
In addition to be an independent marker of shorter survival, SRSF2
mutations were associated with a higher average of mutated genes per patient (4 genes mutated per SRSF2-mutated patient vs 2.1 in the SRSF2 WT cohort (n 5 47), P < .0001). In particular, SRSF2 mutations were associated with mutations of IDH1/2 (n 5 5/9, P < .0001) and ASXL1 (n 5 5/9, P < .05).
| Comparative mutational analysis of MPN and sAML phases
We had 24 pairs of MPN and matched sAML. 12.6-411.2) (P < .001) and accompanied by a significant mean gain of 1.8 mutated genes vs. 0.6 in SRSF2 WT patients (P < .05). Two patients had acquired one mutation of IDH1/2 and two others had acquired one mutation of TP53 (Supporting Information Figure S4 ).
Eight sAML patients had a TP53 mutation. Only 3 of these had already their mutation at the MPN phases and the variant allele frequency (VAF) was always inferior to 15%. For 2 of these 3 patients the VAF increased to approximately 50% (the third was stable a 5% at sAML phase) and the median VAF in the 8 TP53-mutated patients was 34.7% (5.9-83.1). In contrast to SRSF2, TP53-mutated patients at sAML phase had a longer time to sAML transformation than TP53 WT patients, 175 months (range: 70.1-356.7) vs. 71.1 months (range:
12.6-411.2) (P < .01).
Six patients had a TET2 mutation at the sAML phase, 4 of these already presented the mutation at the MPN phase.
| D ISC USSION
Large cohorts of post-MPN sAML are difficult to collect and few studies have been so far dedicated to the molecular evolution of MPNs. 8, 9, 11 To our knowledge, this work presents one of the three larger cohorts of the literature and the first relying on NGS analysis. 3, 12 Leukemic transformation of MPN is classically associated with a very poor prognosis. With a median EFS of 2.9 months and a median OS of 4.7 months, our results are consistent with those previously described. 13 Concerning the frontline therapy, no difference in EFS or OS was observed, between IC or AZA. In the IC treatment group the ORR was of 58.8%, consistent with those published previously. 12, 14, 15 In the same way, in the AZA treatment group the ORR was of 54.6%, consistent with or better than the results previously published. At sAML phase, the three patients of the favorable group had mutations or cytogenetic of de novo AML (NPM1 mutated, t (8; 21) and inv (16)), but only one had a JAK2 mutation whereas all of them where JAK2-mutated at MPN phase. This suggests a sAML independent of the MPN disease (in particular in one of these who had antecedent non-Hodgkin's lymphoma treated with alkylators). They all had a lower OS (maximum of 9 months) than ELN would predict, perhaps because the hematopoiesis environment had been modified during the MPN phase although the patients' age (older than 70 years) may also explain these outcomes.
At MPN phase, as we had previously shown, the molecular profile of patients with MPN who evolved to sAML was different from that of patients with MPN who never transformed, and this profile was very close to the profile observed in sAML. 9 Gene mutations (SRSF2, ASXL1, DNMT3A, IDH1/2, EZH2, TP53. . .) are now known to play a role in transformation but their impact on post-MPN sAML survival has been poorly studied.
In this work, we have shown that sAML patients with mutation in SRSF2 had a shorter OS, a shorter time to transformation to sAML and a higher gain of mutations than patients not mutated for this gene. This is coherent with our previous report of SRSF2 as a gene that may increase the risk of transformation but may not be directly responsible for the transformation. 9 An SRSF2 mutation was reported to be a negative prognostic indicator of poor survival in MF patients (at MPN phase) and to reduce leukemia-free survival. 19 In addition to SRSF2, TP53 and TET2 mutations impacted pejoratively and independently sAML prognosis at acute transformation time.
TP53 and TET2 mutations are common in post-MPN sAML and could be found at MPN phase. 8, 20, 21 TET2 mutations are found in approximatively 12% of MPN and TP53 mutations in MPN phase correlates with age. 22 TP53 mutations in MPN are often difficult to detect because of a very low VAF. 23 If TP53 is well-known for its pejorative impact, TET2
is not considered to have adverse prognostic mutations. 8, 13 In our cohort, TP53 mutations seemed to disadvantage patients treated with IC. In the IC group, patients with TP53 mutation had a lower OS than patients without TP53 mutation.
The role of JAK2, MPL and CALR in MPN is known but their impact in the outcome of MPN is not entirely clear, especially their role in leukemic-free survival. CALR was recently discovered and its prognostic impact is discussed in ET and PMF. [24] [25] [26] [27] Few studies described post-MPN sAML mutated in CALR. In our cohort CALR-mutated patients represented only 12.5% of sequenced sAML. These seemed to have fewer mutations than JAK2 or TN patients and some cellular functions were rarely affected compared to non CALR-mutated patients. Also, 57.1% of CALR-mutated patients had a TP53 mutation, suggesting a special mechanism of transformation.
| CON CL U S I ON
In conclusion, we found that conventional clinical factors (age, karyotype, ELN2017 prognostic classification, treatments received, treatments response, Allo-SCT. . .) failed to predict the patients' outcome. Only the mutational status appeared relevant to predict patients' prognosis at sAML phase. Interestingly, in the patients analyzed, the mutational profile was quite stable between MPN and sAML phases. These results suggest that a more aggressive therapeutic approach could be proposed to patients with a pejorative mutational status, especially at MPN phase.
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